What is SynDevRx?
SynDevRx operates at the intersection of metabolic science and oncology, pioneering the field of Metabo-Oncology. The company is dedicated to transforming cancer treatment by targeting the metabolic drivers and angiogenic factors that facilitate tumor progression. Its lead therapeutic candidate, Evexomostat, represents a novel approach designed to treat patients suffering from metabolic complications while simultaneously enhancing the efficacy of existing standard-of-care therapies. Currently, the organization is focused on validating this innovative platform through clinical trials, with a specific emphasis on breast and prostate cancers. By addressing the needs of an under-treated patient population across various solid tumor types, SynDevRx is positioning itself as a critical player in the next generation of precision medicine.
How much funding has SynDevRx raised?
SynDevRx has raised a total of $18.4M across 3 funding rounds:
Unspecified
$569K
Debt
$16.3M
Debt
$1.5M
Unspecified (2009): $569K, investors not publicly disclosed
Debt (2012): $16.3M, investors not publicly disclosed
Debt (2017): $1.5M, investors not publicly disclosed
Key Investors in SynDevRx
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for SynDevRx?
With the recent capital injection, SynDevRx is well-positioned to accelerate its clinical trial pipeline and expand its research capabilities. The strategic focus will likely remain on the successful progression of Evexomostat through late-stage clinical milestones, which is essential for regulatory approval and eventual commercialization. As the company matures, it will likely seek to strengthen its intellectual property portfolio and potentially explore strategic partnerships with larger pharmaceutical entities to scale its therapeutic reach. The ongoing commitment to metabolic-focused oncology research suggests a long-term strategy aimed at redefining treatment paradigms for patients with complex, solid-tumor malignancies.
See full SynDevRx company page
